Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as URO-902
hMaxi-K · 3 trials · 3 indications
Physical examination of the penis included inspection and palpation.
Clinical significance was determined by the Investigator using central laboratory values.
Clinical significance was determined by the Investigator using central laboratory values.
Average daily number of urgency episodes was calculated as the total number of urgency episodes recorded on a completed diary day within the visit window divided by the number of days the Bladder Diary was filled out. An urgency episode was defined as when a participant answered "Yes" to the question "Need to urinate immediately" on the bladder diary electronic case report form (eCRF). If a participant had more than 1 bladder diary filled out on the same day, then all the urgency episodes were summed together. The denominator used for calculating the average number only counted the days in which there was at least 1 completed bladder diary day within the visit window. Baseline was defined as the last non-missing measurement prior to the study treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
| Arm | Type | Description |
|---|---|---|
| hMaxi-K | ACTIVE_COMPARATOR | Single Treatment/ two escalating dose levels (8000 µg and 16,000 µg injection). In each dose level, 11 participants will receive hMaxi-K and 6 will receive placebo (only one injection per each participant) |
| Placebo (PBS-20% sucrose) | PLACEBO_COMPARATOR | PBS-20% sucrose administered during two single treatment dose levels (8000 µg and 16000 µg) by injection (only one injection per each participant) |
| Cohort 1: URO-902 24 mg; Placebo | EXPERIMENTAL | Participants will receive either a single treatment of URO-902 24 milligrams (mg) or matching placebo. |
| Cohort 2: URO-902 48 mg; Placebo | EXPERIMENTAL | Participants will receive either a single treatment of URO-902 48 mg or matching placebo. |
| hMaxi-K 16000 µg | EXPERIMENTAL | Single treatment (16000 µg by 20 intramuscular injections). A total of 6 participants will receive hMaxi-K, and 3 will receive placebo. |
| hMaxi-K 24000 µg | EXPERIMENTAL | Single treatment (24000 µg by 30 intramuscular injections). A total of 6 participants will receive hMaxi-K, and 3 will receive placebo. |
| Name | Type | Description |
|---|---|---|
| hMaxi-K Single Treatment/ 2 escalating dose levels (8000 µg and 16000 µg injection) | DRUG | - |
| Placebo (PBS-20% sucrose) | DRUG | - |
| URO-902 | DRUG | intradetrusor injection |
| Placebo | DRUG | intradetrusor injection |
| hMaxi-K | DRUG | Single treatment/2 escalating dose levels (16000 µg and 24000 µg by intramuscular injection) |
Inclusion Criteria: * Eligible participants must meet the following inclusion criteria: 1. Signed Informed Consent 2. Be adult males over 18 years of age diagnosed with erectile dysfunction and whose ED is attributable to an underlying, stable medical condition such as hypertension and atheros...
hMaxi-K is being developed for erectile dysfunction and overactive bladder. It has been studied in a Phase 2A trial in men with erectile dysfunction and a Phase 1 study in women with overactive bladder. It is an investigational gene therapy and has not been approved for any indication.
hMaxi-K is being developed by Roivant Sciences Ltd., which trades on the Nasdaq under the ticker ROIV. The company is responsible for the clinical development program, including the completed Phase 2A trial in erectile dysfunction and the Phase 1 study in overactive bladder.
hMaxi-K is in Phase 2 development. A Phase 2A clinical trial in erectile dysfunction has been completed, and a Phase 1 study in overactive bladder has also been completed. There are currently no active trials listed for hMaxi-K.
hMaxi-K has been studied in two completed clinical trials: NCT02713789, a Phase 2A trial in erectile dysfunction that enrolled 26 men in Kuwait, and NCT01870037, a Phase 1 study in overactive bladder that enrolled 13 women in the United States. Both trials are completed.